Visa’s Growing Services Business Infused with New AI-Powered Products
Today, Visa (NYSE:V), a leader in digital payments, announced continued expansion of its global value-added services business with the addition of three new AI-powered risk and fraud prevention solutions. The new products, part of the end-to-end Visa Protect suite, are designed to reduce fraud across immediate account-to-account and card not present (CNP) payments, as well as transactions both on and off Visa’s network.
Visa Protect is part of a broad suite of Visa value-added services that have grown to nearly 200 products, spanning five high-demand categories: Acceptance, Advisory, Issuing, Open Banking, and Risk and Identity. To help clients navigate a growing number of complexities, Visa has combined decades of expertise and significant investments in both AI and fraud prevention, with $10 billion over the last five years alone in technology and innovation, to help reduce fraud and increase network security.
“Digital payments go far beyond completing a sale – we are entering an era of modern commerce where winners move fast, AI is essential, experiences are flexible and security is native,” said Antony Cahill, Global Head of Value-Added Services, Visa. “Businesses are looking for partners that can enable their ambitions to compete and win and we’re proud to be the trusted partner helping a growing number of clients do exactly that in today’s highly competitive environment.”
Security and fraud prevention are fundamental to Visa. Last year, Visa helped block $40 billion in fraudulent activity, nearly double from the year prior2. Today’s announcement focuses on three Visa Protect solutions that are intended to address client needs and utilize the company’s deep expertise in AI:
- Visa Deep Authorization (VDA): Developed to address challenges facing issuers as a result of increasingly sophisticated digital fraud, VDA is a new transaction risk scoring solution tailored to better manage CNP payments. Powered by a world-class deep learning recurrent neural network (RNN) model and petabytes of contextual data, VDA is designed to combat fraud without disrupting digital transaction experiences.
- Expansion of Visa Advanced Authorization (VAA) and Visa Risk Manager (VRM) for non-Visa card payments: Visa’s extensive, AI-powered fraud risk management solutions are now network scheme agnostic, allowing issuers to simplify their fraud operations into a single fraud detection solution that help strengthen fraud protections while reducing costs.
- Real-Time, Account-to-Account Payment Protection: Visa’s first fraud prevention solution built specifically for immediate payments, including P2P digital wallets, account to account transactions, and central banks’ instant payment systems. Powered by deep learning AI detection models, this new service provides a risk score in real time that helps financial institutions prevent fraud by automatically blocking bad transactions before they happen.
Each product will launch in the first half of 2024. Availability will vary by product and market.
“Real-time, digital payments are nearly ubiquitous, creating a need for security solutions that are transformative and adaptive to the real-world,” said James Mirfin, SVP, Global Head of Risk and Identity Solutions, Visa. “As digital fraud grows in volume and sophistication, Visa is keeping pace by bolstering our powerful suite of risk and fraud solutions through our unmatched technology innovation and AI expertise, and expanding their utility beyond the Visa network.”
To learn more about end-to-end security solutions from Visa, visit our Intelligent Security page and Visa.com for more information on Visa’s value-added services for businesses.
About Visa Inc.
Visa (NYSE: V) is a world leader in digital payments, facilitating transactions between consumers, merchants, financial institutions and government entities across more than 200 countries and territories. Our mission is to connect the world through the most innovative, convenient, reliable and secure payments network, enabling individuals, businesses and economies to thrive. We believe that economies that include everyone everywhere, uplift everyone everywhere and see access as foundational to the future of money movement. Learn more at Visa.com.
1
Visa 2023 Annual Report
2 Visa data from October 1, 2022 – September 30, 2023
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240327525747/en/
Contact information
Kryssa Guntrum
kguntrum@visa.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ASISA Partners with HCLTech to Drive Digital Transformation and Expansion in Iberia17.6.2025 14:41:00 EEST | Press release
HCLTech, a leading global technology company, has been selected by ASISA, a prominent health insurance provider in Spain, as its strategic IT partner to accelerate business transformation and expansion in Iberia. This partnership aims to accelerate ASISA's digital transformation journey to enhance the experience for its 2.2 million customers and position the company at the forefront of innovation in the region. HCLTech will modernize ASISA's IT platforms and leverage AI-based solutions to enhance business efficiency. The comprehensive mainframe modernization and solutions from HCLTech will enable ASISA to create a more agile, responsive IT infrastructure. “Partnering with HCLTech marks a key step in our digital transformation journey. By modernizing our platforms and embracing cutting-edge technologies, we are reinforcing our commitment to delivering exceptional service to our customers,” said José Pereira, CTO at ASISA. “This collaboration will empower ASISA with a more agile, scalabl
Biocytogen Responds to Harbour BioMed’s Patent Claims: RenNano® is an Independently Developed Platform with Distinct Innovation and Full Legal Standing17.6.2025 14:00:00 EEST | Press release
In response to Harbour BioMed’s recent press release regarding a procedural development in their ongoing legal claim, Biocytogen issues the following statement: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250617098086/en/ Figure 1. Biocytogen’s RenNano® Platform Genetic Engineering Strategy (Source: https://biocytogen.com/antibody-drug-development/rennano） Biocytogen stands by its core values of independent innovation, respect for intellectual property, and a commitment to fair competition. The RenNano® platform is the result of independent, original R&D, based on Biocytogen’s proprietary genome editing technologies. Its technical principles, design strategy, and IP scope are fundamentally different from the patents in dispute. 120 vs. 9 – A Significant Technical Divide of RenNano® Platform; Biocytogen Will Resolutely Take Legal Actions to Protect Its Rights The RenNano® platform employs a large-fragment knock-in strategy
EDB Postgres ® AI Accelerates New Era of Sovereign Data and AI for Enterprises, Industries, and Nations17.6.2025 14:00:00 EEST | Press release
EnterpriseDB (EDB), the leading Postgres data and AI company, today announced new innovations to the EDB Postgres AI (EDB PG AI) platform designed to help enterprises deploy and scale AI securely and compliantly across their Postgres environments, whether in clouds or on-premises. The platform streamlines operations at scale, integrates easily with existing data ecosystems, and centralizes hybrid management and observability in a single AI-ready control plane for the emerging era of agentic AI. See the demonstrations and configure your sovereign AI and platform at www.enterprisedb.com. EDB PG AI is a unified platform with an easy-to-use interface for managing transactional, analytical, and AI workloads. As the industry’s first Postgres-based sovereign data and AI platform, it unifies relational and non-relational data in a single system, featuring automatic pipelines and built-in development tools that seamlessly automate and operationalize data for AI. “In this AI-first, sovereign-fir
G42 and Liquid AI Partner to Deliver Private, Local and Efficient AI Solutions to Enterprises at Scale17.6.2025 13:00:00 EEST | Press release
G42, the Abu Dhabi-based global technology group, and Liquid AI, a leading efficient foundation models company headquartered in Cambridge, Massachusetts, today announced that they have entered into a multifaceted commercial partnership to facilitate the creation, training and commercialization of generative AI solutions powered by Liquid Foundation Models. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250617744482/en/ The goal of the partnership is to jointly develop and deploy private generative AI solutions internationally, from the Middle East and North Africa to the Global South, and across many sectors, such as investment and banking, consumer electronics, telecommunications, biotech, and energy. G42 companies such as Core42 and Inception are involved in various aspects of the partnership, from AI infrastructure for AI development to co-designing multimodal foundation models and deployment. “This partnership reflects o
Ferrer Receives FDA Fast Track Designation for FNP-223 in Progressive Supranuclear Palsy (PSP)17.6.2025 11:28:00 EEST | Press release
Ferrer, a B Corp-certified international pharmaceutical company, has announced that FNP-223, a novel therapy in-licensed from Asceneuron and aimed at slowing the development of progressive supranuclear palsy (PSP), has received Fast Track designation from the US Food & Drug Administration (FDA). FNP-223, a new molecular entity in active development for PSP, is in an ongoing Phase 2 study to evaluate its safety, efficacy, and pharmacokinetics in adult patients with possible or probable PSP-Richardson syndrome (PSP-RS), the most common clinical variant of this neurodegenerative disease1. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250617437460/en/ Ferrer's pharmaceutical production plant in Sant Cugat del Vallés, Barcelona, Spain. “We are thrilled to receive Fast Track designation from the FDA for FNP-223 in the treatment of PSP. Consistent with our purpose of using business to fight for social justice, we are committed to
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom